SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (2322)3/2/2001 11:56:08 AM
From: biowaRead Replies (1) of 4974
 
Rick,

Just wanted to echo Miljenko's comments, differentiating between "a MAJOR clinical success," and just a solid company executing on their clinical development plan successfully. As Miljenko says, I'm not sure where the MAJOR success is waiting in the wings.

Also, to be technically correct, Viracept was not really a MAJOR clinical success, it was more of a MAJOR marketing success. It was a me-too drug, that in terms of viral load reduction wasn't significantly better than other already marketed protease inhibitors and close-in clinical candidates. What made Viracept was at least a moderately better side effect profile (especially nuisance side effects), and the marketing foresight to realize that they could key on that.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News